Synopsis:
This study is evaluating safety and efficacy of a water-free tacrolimus ophthalmic solution (NOV05) for the treatment of non-infectious anterior uveitis (NIAU) sponsored by Novaliq. It will enroll approximately 20 participants across four U.S. centers. Treatment duration is 6 weeks followed by an observation period of 2 weeks. Participants will receive either a low dose or a high dose or NOV05.
NOV05 is a water-free eye drop containing tacrolimus, a steroid- free potent immunomodulator with strong anti-inflammatory properties. For the solubilization of tacrolimus in NOV05 the semifluorinated alkane, perfluorobutylpentane, is used, which is an inactive ingredient approved for ophthalmic use in the product Vevye®. Due to its unique physicochemical properties, this vehicle increases local bioavailability of the tacrolimus in the target tissues for NIAU, iris and ciliary body.
For updates and other study sites see: Study Details | NCT07285070 | Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis | ClinicalTrials.gov
Synopsis:
This trial is studying the safety and efficacy of Brepocitinib to treat non-infectious intermediate, posterior and panuveitis. This medication has moved to phase 3 for further testing after recently completing a phase 2 trial, and is a dual inhibitor of JAK1 and TYK2, both thought to play important roles in managing inflammation and autoimmunity. This trial is currently enrolling participants in the US and internationally, and is designed to include two phases for participants, first with an active drug versus placebo phase, followed by an open-label phase where everyone is treated with Brepocitinib.
For more information on if you quality and to find a local site, click here:
https://clarityuveitis.com/
For updates on results of this trial, click here: https://clinicaltrials.gov/study/NCT06431373
Synopsis:
This trial is further evaluating the safety and efficacy of YUTIQ after FDA approval. YUTIQ is a steroidal intravitreal implant for the treatment of non-infectious posterior uveitis. This study does not have a placebo arm and therefore all eligible participants are treated with YUTIQ. This has completed enrollment, and patients are progressing through scheduled follow-ups.
For updates on results of this trial, click here: https://clinicaltrials.gov/study/NCT05322070
Synopsis:
This trial is studying the safety and efficacy of izokipeb, a subcutaneous biologic injection, which modifies the immune system by targeting Interleukin-17A for the treatment of non-infectious intermediate, posterior, and panuveitis. This trial has completed enrollment, and patients are
continuing to progress through follow up visits.
For updates on results of this trial, click here: https://clinicaltrials.gov/study/NCT05384249
Synopsis:
This trial is studying the safety and efficacy of ESK-001, an oral medication for the treatment of non-infectious intermediate, posterior and panuveitis. This trial offers two alternative doses of ESK-001, an oral medication which acts as an allosteric tyrosine kinase 2 (TYK2) inhibitor, thought to play a role in inflammation. This trial has completed enrollment.
For updates on results of this trial, click here: https://clinicaltrials.gov/study/NCT05953688
Synopsis:
Taltz (ixekizumab) is an FDA-approved, biologic drug that modifies the immune system by targeting Interleukin-17A. Taltz is currently used to treat moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis. This study explored the safety and efficacy of Taltz for the treatment of adults with non-infectious uveitis. Enrollment for this trial has been completed and results are currently being analyzed.
For updates on results of this trial, click here: https://clinicaltrials.gov/study/NCT06085079
Synopsis:
Cartesian Therapeutics developed an infusion therapy, Descartes-08, which uses re-engineered T-cells from a patient’s body to treat different diseases and conditions. By giving the T-cells a new message not to target your cells as enemy cells, the inflammatory response can be reduced or inhibited. This innovative infusion treatment was offered for patients with active Ocular Cicatricial Pemphigoid (OCP) and Autoimmune Retinopathy through FDA Exanded Access, but is not currently enrolling new patients.
Synopsis:
This is a collaboration project with researchers at UMass Chan Medical School that are hoping to learn more about the role of regulatory T cells (immune cells) in those with ocular inflammatory diseases, such as uveitis. Any patient getting bloodwork done at MERSI in Waltham, Ma for their regular appointments is eligible to provide an additional blood sample.
Synopsis:
This is a collaboration project with researchers at TScan Therapeutics who are hoping to learn more about the role of regulatory T cells (immune cells) in those with autoimmune disorders, specifically birdshot chorioretinopathy. Patients with birdshot chorioretinopathy who are already receiving an anterior chamber paracentesis or vitrectomy procedure at MERSI in Waltham, MA may be eligible to provide an additional eye fluid sample for compensation.
Synopsis:
This is a collaboration project with Boston Children’s Hospital to learn more about autoimmune diseases of the eye to improve diagnosis and treatment of these diseases. Any patient undergoing surgery, either with or without an inflammatory eye condition, qualifies for this trial if they are willing to provide a sample of blood and sample of eye fluid while undergoing surgery.
 |
|
|
|
